Acutus Medical, INC 8-K filings

Acutus Medical, Inc. (OTC: AFIB) announced a significant increase in revenue from continuing operations for the full year 2024, alongside improvements in operating loss and gross margin.

Acutus Medical terminates its registration rights agreement with Deerfield Funds as part of its plan to deregister its common stock and cease periodic reporting obligations.

Acutus Medical is significantly downsizing its operations and transitioning its CEO and CFO to consulting roles as it focuses on fulfilling its obligations to Medtronic for left-heart access product manufacturing.

Acutus Medical has amended its credit agreement with Deerfield Partners, adjusting the loan amortization schedule and increasing the exit fee.

Acutus Medical reports a 156% year-over-year increase in third-quarter revenue from continuing operations, alongside a strategic realignment towards left-heart access products.

Acutus Medical has reached a settlement with Biotronik, resolving a dispute over multiple agreements and terminating those agreements, while also agreeing to potential future payments based on certain events.

Acutus Medical saw a 172% year-over-year increase in revenue from continuing operations and a 47% reduction in operating expenses in the second quarter of 2024.

Acutus Medical held its annual meeting on June 13, 2024, where stockholders elected two Class I directors and ratified the appointment of KPMG LLP as the company's independent auditor.

Acutus Medical's common stock will be delisted from the Nasdaq and is now trading on the OTC Pink Market after failing to meet listing requirements.

Acutus Medical reported a significant 192% year-over-year revenue increase in the first quarter of 2024, driven by its focus on left-heart access products, while also undergoing a strategic restructuring.

Acutus Medical, Inc. has received notification from Nasdaq that it will be delisted due to non-compliance with minimum bid price and stockholders' equity requirements, with trading to be suspended on May 9, 2024.

Acutus Medical announced its 2023 financial results, highlighting a strategic shift to focus on manufacturing and distributing Medtronic's left-heart access products.

Acutus Medical has amended its credit agreement with Deerfield Partners to waive potential defaults arising from an arbitration demand and modify terms related to a possible Nasdaq delisting.

Acutus Medical has received notice from Biotronik terminating their distribution agreements, alleging breach of contract and seeking damages.

Acutus Medical's Board of Directors saw the resignation of its chairperson, R. Scott Huennekens, and the appointment of Shaden Marzouk as the new independent chairperson, both effective January 15, 2024.

Acutus Medical has announced the departure of its CEO, David Roman, effective January 7, 2024, and the appointment of Takeo Mukai as the new CEO, effective January 8, 2024, along with a consulting agreement with the former CEO.